Introduction
New clinical trial designs. Phase 0 trials
Adaptive trial designs
Targeting multiple pathways with multiple drugs
Preclinical model systems
Molecular imaging. Current and developing methods
Challenges of molecular imaging
Screening for predictive markers. The challenges of clinical validation
Bioimaging predictive markers
Clinical translation
Panel discussion
Costs of clinical trials. Regulatory costs
Patient accrual
Global outsourcing
Time is money
Public-private collaborations
Regulatory issues. Regulatory barriers to innovation
Patient advocacy perspective
Regulation of in vitro diagnostics
Regulatory issues in improving cancer clinical trials
Reports from the case study discussion groups. Adaptive trial design
Phase 0 trials
Imaging
Use of proteomics/genomics to assign therapy in lung cancer
Use of genetics/genomics to assign therapy.